NCT04936113View on ClinicalTrials.gov

Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

June 2, 2021

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

FB-401

Topical

Trial Locations (8)

30263

MedaPhase, Inc, Newnan

32055

Multi-Specialty Research Associates, Inc., Lake City

40241

DS Research, Louisville

47129

DS Research, Clarksville

55112

Cyn3rgy Research, New Brighton

77401

Bellaire Dermatology Associates, Bellaire

94538

Center for Dermatology Clinical Research, Inc., Fremont

97030

Cyn3rgy Research, Gresham

Sponsors
All Listed Sponsors
lead

Forte Biosciences, Inc.

INDUSTRY

NCT04936113 - Continued Safety Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis Previously Enrolled in the FB401-01 Study | Biotech Hunter | Biotech Hunter